Bleeding risk in patients using Botox treatments and blood thinners

“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.

In this video, Jai Seth, MD, discusses the findings of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.

Related Content:

OAB and IncontinenceUTv
Questions raised by kidney cancer epidemiology update
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
Breakthrough Advances in Immunotherapy